Tirzepatide (Mounjaro, Zepbound) represents a breakthrough in type 2 diabetes and weight management as the first dual GIP/GLP-1 receptor agonist approved by the FDA
Verma S, et al
As with all incretin-based therapies, retatrutide's side effect profile is closely linked to its receptor pharmacology
From the most common to the least common, they include [23]: Injection site reactions, like pruritus, rash, pain, and swelling (3.1%) Arthralgia (2.4%) Pain in the extremities (1.1%) Myalgia (1.1%) Peripheral edema (1.1%) Paresthesia (0.9%) Hypoesthesia (0.7%) Rash (0.7%) Dysepsia (0.3%) Muscle pain (0.3%) Pruritus (0.3%) Vomiting (0.3%) Muscle stiffness (0.3%) Carpal Tunnel Syndrome (0.2%) Joint swelling (0.2%) Night sweats (0.2%) Palpitations (0.2%) Use in Specific Populations In addition to the adverse effects listed above, researchers must be extra cautious when administering tesamorelin to test subjects in the following populations: Individuals with hypothalamic-pituitary axis issues
Established half-life and bioavailability parameters n.d
Dani at the front is always so sweet and welcoming, and the whole staff makes you feel genuinely cared for